Table 1 Multivariate analysis of RPS6KA1 and USP1 in AML patients.
Covariate | Level | Hazard ratio | 95% CI Low | 95% CI Up | HR P-value | Type3 P-value |
|---|---|---|---|---|---|---|
USP1 | >median | 1.26 | 1.02 | 1.56 | 0.032 | 0.032 |
<median | – | – | – | – | ||
RPS6KA1 | >median | 1.42 | 1.15 | 1.76 | 0.001 | 0.001 |
<median | – | – | – | – | ||
FLT3 | >median | 1.09 | 0.89 | 1.35 | 0.407 | 0.407 |
<median | – | – | – | – | ||
Sex | M | 1.05 | 0.85 | 1.30 | 0.643 | 0.643 |
F | – | – | – | – | ||
Race | Others | 0.85 | 0.64 | 1.12 | 0.247 | 0.247 |
White | – | – | – | – | ||
ELN2017 risk | Favorable | 0.43 | 0.32 | 0.58 | <0.001 | <0.001 |
Intermediate | 0.77 | 0.61 | 0.97 | 0.029 | ||
Adverse | – | – | – | – |
